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Hysterectomy with tubo-ovarian conservation and tubal sterilization per-se are associated with a 30% reduction in OC risk, 8, 9 and the additional benefit from salpingectomy above this has not been precisely defined. Prospective high quality data for OBS showing a reduction in OC risk are lacking Whether OBS will lead to early menopause is unknown. Available data on ovarian function post salpingectomy are few/limited and restricted to short term outcomes of hormonal levels and ovarian blood flow indices. 12 However, these correlate with ovarian reserve in relation to fertility rates, oocyte retrieval and IVF outcomes, 13 and are not predictive of risk for premature menopause. There are no validated hormonal cut-points that predict the length of the menopausal transition or final menstrual period. 14, 15 Assessment of a longitudinal trend/change in hormonal levels (and menstrual periods) over a period of years following OBS is critically important to assess impact on menopause. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 This is relevant given the detrimental impact of premature surgical menopause on cardiovascular, bone, neurological heath and mortality. 16 Another important issue of concern is potential training implications for clinicians/O&G trainees in the UK: highlighted by 21%/49% respectively. 38% of less experienced (<8years post MRCOG) compared to 12% more experienced (>23years post MRCOG) clinicians felt they would benefit from additional training (p<0.005). This is higher compared to 15% Canadian O&Gs who felt additional surgical training would be beneficial. 10 Views/practice also varies by experience and place of work. More experienced UK clinicians (63% of highest quartile vs 26% in lowest quartile) felt that OBS should only be introduced within a clinical trial(p=0.0002). Clinicians in university/teaching hospitals (U/TH) compared to district general hospitals(DGH) were more likely to support the tubal hypothesis (66% vs 56%, p=0.008), perform OBS (43% vs 28%, p=0.034) and support its introduction into clinical practice (56% vs 44% p=0.043).
While clinicians working at DGH compared to U/TH report greater concerns for lack of long term outcome data (p=0.019), RCT evidence of benefit (p=0.011) and implications for training for self (p=0.035) and trainees (p=0.043).
We found a significant lack of awareness regarding the reduction in OC risk associated with tubal ligation and hysterectomy itself with 72-76% respondents being unaware of this. It is possible that enthusiasm for OBS outside a study may be further tempered had these facts been better known. A 6% regret/reversal rate has been reported for women undergoing sterilization. 17 This emerged as another important issue given the irreversibility of salpingectomy compared to ligation. Paucity of cost-effectiveness data was considered a limitation by 45% respondents. A recent study from British
Columbia suggests OBS may be cost-effective assuming a '50%' reduction in OC risk and 'no' detrimental impact on menopause/ovarian function. 18 However, prospective data confirming these 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 levels of beneficial outcomes along with utility scores for salpingectomy are lacking, maintaining uncertainty on this issue. Further prospective studies on cost-effectiveness of OBS are needed.
There is a pressing need to develop consensus on whether or not OBS should be offered primarily within a clinical trial in the UK. This may also be of relevance to other countries debating this issue.
While a number of charities, patient groups and learned societies 3, 4 have advocated offering OBS, the need and importance of further trials has also been recognised, 3 with some suggesting this be offered only within a clinical trial. 19 It is important to ensure that any introduction of OBS into clinical practice does not hinder/prevent collection of prospective good quality evidence to validate its efficacy in preventing OC and understand implications on long-term health outcomes. A cohort study will not adequately answer the question of additional impact of OBS over standard surgery. A two arm RCT with OC as the primary outcome would require a multicentre international study of ~100,000 women (51,600/arm) and 10year follow-up (for a 30% difference between arms, 80% power, α=0.05, assuming annual OC incidence of 30/100,000). This will be difficult to fund. A pragmatic and plausible way forward which addresses a key issue would be a RCT with menopause as the primary outcome. A sample size of 7026 women (3513/arm) will detect a HR=1.2 or 4690 (2345/arm) a HR=1.25 (90% power, α=0.05; assuming: 20% event rate, 10% withdrawal rate). This will also address various secondary outcomes highlighted above. Moreover, it is important that all cases of OBS undertaken clinically at benign surgery be properly recorded using a separate hospital code to enable linkage for long term follow-up and data collection. The strength of the argument for change in practice needs to be driven by the magnitude of the additional benefit of OBS on OC risk, weighed against the implications for logistics of delivery, impact on training needs, potential complications, additional costs, and long-term health outcomes of early menopause and its consequences. The RCOG and its subspecialist societies as well as international bodies like ESGO and IGCS have an important role to play in this. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 
